Phase Ⅱc Sutdy of Aolanti Weikang Tablets in FD PDS Patients

Inclusion Criteria: * Patients diagnosed with FD according to the ROME Ⅳ criteria，and must with symptom of bothersome postprandial fullness; * Patients diagnosed with Stagnation of Qi according to traditional Chinese medicine; * At least the symptom of bothersome postprandial fullness ≥4 on the Visual Analogue Scale(VAS), and the number of recurrence day must ≥3 in one week; * Provides voluntary informed consent after receiving adequate explanation and demonstrates thorough understanding of the nature of the study. Exclusion Criteria: * The patients with high placebo effect, the scores in placebo run-in stage declined much than 30 percent of the mean VAS per week compare to blank run-in stage; * Unable to take drugs orally; * Within 7 days of Screening, the average number of stool \> 2 times/day; * Within 7 days of Screening, with the presence of ≥ type 5 stool form per the Bristol Stool Form Scale; * History of drug or aurantium allergy; * Patients with positive in fecal occult blood test; * Abnormal liver and/or kidney function: creatinine \>1.5\*ULN (upper limits of normal), and/or AST and/or ALT \> 2.0\*ULN, and/or TBil \> 1.5\*ULN; * Patients with family history of prolonged QT syndrome or have history of torsional apical ventricular tachycardia; or QTc \> 480 ms; * Digestive diseases, or other diseases within 6 months before Screening that may affect the swallow, absorption, or metabolism of study drugs, and not yet fully recovered judged by the Investigator; * Patients who positive in H. Pylori test plan to accept the H. pylori eradication therapy within the trial; * Serious complications (heart, brain, lung, liver, kidney, or blood disease); * Neuropsychiatric disorders; * Use of prohibited medications; * Pregnant or lactating women or those who are planning to conceive during the study period; * Drug abuse within 3 months, or alcohol abuse within 6 months; * Patients participated in other clinical trials within 30 days before taking drugs; * Other conditions deemed ineligible for enrollment by Investigator.